Nasser Altorki talks through the high PD-L1 expression sub-analysis findings from the IMpower010 trial of adjuvant atezolizumab versus best supportive care for stage II–IIIA NSCLC (5:37).
Nasser Altorki talks through the high PD-L1 expression sub-analysis findings from the IMpower010 trial of adjuvant atezolizumab versus best supportive care for stage II–IIIA NSCLC (5:37).
Don’t fall behind!
Get the latest headlines – in your specialties of choice – delivered straight to your inbox.
medwireNews Deputy Bureau Chief
© 2023 Springer Healthcare Limited.
Part of the Springer Nature Group.
